Pluri Inc. (NASDAQ:PLUR) Short Interest Update

Pluri Inc. (NASDAQ:PLUR) was the target of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 22,147 shares, an increase of 22.7% from the January 15th total of 18,051 shares. Based on an average daily trading volume, of 10,055 shares, the short-interest ratio is currently 2.2 days. Currently, 0.3% of the shares of the company are sold short. Currently, 0.3% of the shares of the company are sold short. Based on an average daily trading volume, of 10,055 shares, the short-interest ratio is currently 2.2 days.

Pluri Stock Performance

NASDAQ:PLUR opened at $3.67 on Thursday. Pluri has a 52 week low of $2.82 and a 52 week high of $7.13. The firm’s 50-day simple moving average is $3.27 and its 200 day simple moving average is $3.97. The firm has a market cap of $36.88 million, a price-to-earnings ratio of -0.75 and a beta of 0.67.

Pluri (NASDAQ:PLUR) last announced its earnings results on Thursday, February 12th. The company reported ($0.71) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.06). The business had revenue of $0.20 million for the quarter, compared to analysts’ expectations of $0.64 million.

Hedge Funds Weigh In On Pluri

An institutional investor recently bought a new position in Pluri stock. Jane Street Group LLC purchased a new position in shares of Pluri Inc. (NASDAQ:PLUR) in the first quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned 0.14% of Pluri at the end of the most recent quarter. Institutional investors and hedge funds own 16.59% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pluri in a research report on Thursday, January 22nd. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $12.00.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.